Revance Therapeutics Soars on Phase 3 Data -- Biotech Movers

 | Dec 05, 2017 | 9:34 AM EST
  • Comment
  • Print Print
  • Print
Stock quotes in this article:






Shares of Revance Therapeutics Inc. (RVNC) surged 30.8% to $34 in premarket trading on Tuesday, Dec. 5, after the Newark, Calif.-based firm unveiled positive top-line results from a pair of Phase 3 studies evaluating RT002 for the treatment of glabellar, or frown, lines.

Revance said it thinks that RT002, if approved by the U.S. Food and Drug Administration, would be the first neuromodulator with a duration of six months. "Marketed neuromodulators have demonstrated duration of three to four months in treating glabellar lines," the company noted.

Meanwhile, shares of Arena Pharmaceuticals Inc. (ARNA) rose 1.3% to $30 after the San Diego firm and Everest Medicines Ltd. inked a development and commercialization partnership for ralinepag and etrasimod in mainland China, Taiwan, Hong Kong, Macau, and South Korea.

The agreement gives Everest exclusive rights to develop and commercialize ralinepag and etrasimod in those areas.

Arena will receive an upfront payment of $12 million and is eligible to receive up to $212 million in development and commercial milestone payments. In addition, Arena is entitled to receive up to low double-digit royalties on net annual sales of both ralinepag and etrasimod.

Arena is developing ralinepag, a potential treatment of pulmonary arterial hypertension; and etrasimod, which is being evaluated for autoimmune diseases.

Among the other biotech movers was Immunomedics Inc. (IMMU) , up 3.3% to $9.30. 


Columnist Conversations

View Chart »  View in New Window » BA chart I'm STALKING this one for a buy trigger........
View Chart »  View in New Window »   WEEKLY
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...
BABA is still dancing on key weekly support here.  Wait for a trigger! View Chart »  Vi...



News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.